Erste Asset Management Gmb H Seagen Inc. Transaction History

Erste Asset Management Gmb H

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Nov 26, 2024	SELL	$0.0 - $228.9 $0 - $12.2 Million	-53,349 Closed	0 $0
Q3 2023 Nov 26, 2024	BUY	$191.51 - $216.16 $1.8 Million - $2.03 Million	9,399 Added 21.39%	53,349 $11.3 Billion
Q2 2023 Nov 26, 2024	BUY	$187.64 - $206.25 $167,562 - $184,181	893 Added 1.73%	52,499 $10.1 Billion
Q1 2023 Nov 26, 2024	BUY	$127.59 - $203.08 $976,829 - $1.55 Million	7,656 Added 17.42%	51,606 $10.5 Billion
Q4 2022 Nov 26, 2024	BUY	$117.37 - $139.17 $422,532 - $501,011	3,600 Added 8.92%	43,950 $5.64 Billion
Q3 2022 Nov 26, 2024	BUY	$135.27 - $180.11 $5.95 Million - $7.92 Million	43,950 New	43,950 $5.96 Billion
Q2 2022 Nov 26, 2024	BUY	$108.81 - $179.33 $4.39 Million - $7.24 Million	40,350 New	40,350 $7.23 Billion
Q1 2022 Nov 22, 2024	BUY	$119.61 - $157.85 $1.14 Million - $1.5 Million	9,500 Added 30.79%	40,350 $5.71 Billion
Q4 2021 Nov 22, 2024	BUY	$142.57 - $190.86 $6.39 Million - $8.56 Million	44,850 New	44,850 $7.13 Billion
Q4 2020 Nov 22, 2024	BUY	$164.63 - $211.93 $5.08 Million - $6.54 Million	30,850 New	30,850 $5.74 Billion

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Erste Asset Management Gmb H, based on Form 13F filings with the SEC.

Stay updated on Erste Asset Management Gmb H with notifications on news.